Medison Pharma Declares a Multi-Regional Partnership Agreement with argenx Across Europe and Israelto Commercialize Efgartigimod

On June 6, 2022, - Medison Pharma ("Medison"), an international pharma company fixated on delivering access to highly innovative therapies to patients in global markets, announced an exclusive multi-regional agreement to commercialize efgartigimod with argenx in 14 countries, including Poland, Hungary, Czech Republic, Romania, Slovenia,  Bulgaria, Lithuania, Croatia, Slovakia, Estonia, Greece, Cyprus, Latvia, and Israel for the treatment of adult patients suffering from general myasthenia gravis.

According to Meir Jakobsohn, the Founder and CEO of Medison, the company is on a mission to help patients with critical, rare diseases in getting faster access to exceedingly innovative therapies, irrespective of their place of residence in the world. Moreover, he also added that by collaborating with argenx, they wouldenable a force multiplier for this advance therapy, thus helping to save and improve the lives of the patients suffering from generalized myasthenia gravis.

The Vice President-International Markets at Medison, Victor Papamoniodis, stated that the organization is proud to collaborate with argenx and help expand its reach to treat patients with severe autoimmune diseases in the 14 countries. Medison is looking forward to utilizing its unique commercial platform and applying its expertise to ease faster access to this new therapy for patients all across their markets.